GI Partners Acquires CDMO and Cell Solutions
As Rose BioSolutions, the established CDMO and Cell Solutions businesses continue to support the biotechnology ecosystem with cell sourcing capabilities and CDMO services to accelerate your advanced therapy from development to delivery.
Learn More
Explore the CGT Incubator and Accelerator Programs
CIP/CAP Overview
To support and expedite the development of life-changing therapies for patients in need, biotechnology pioneers with extraordinary ideas and potential are invited to apply to take part in Charles River's Incubator and Accelerator Programs.
| Program | Stage of Development |
|---|---|
| Incubator Program (CIP) | 24+ months from IND or CTA submission |
| Accelerator Program (CAP) | 18-24 months from IND or CTA submission |
With the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment, the programs enable early-stage developers to ultimately form a strong foundation for commercial viability.
"The selection of Charles River as our CDMO resulted from the additional benefits of its CGT Accelerator Program, including manufacturing prioritization for Nav 1.7, introduction to key industry players, scientific advisory and consulting services, plus co-marketing efforts. We are delighted to have been selected from a pool of talented applicants."
Ana Moreno, PhD, Chief Executive Officer, Navega Therapeutics, Inc.
Leverage Integrated CGT Expertise
Integrated within Charles River's extensive virtual and physical global network, the programs are bolstered by world-class advisory services, amalgamating a cross-functional team of scientific, regulatory, and manufacturing experts in:
- Drug Discovery and Safety Assessment
- Research Models and Services
- Cell Sourcing
- Contract Development, Manufacturing, and Testing
- QC Microbial Solutions
"Jaan Biotherapeutics, Inc. is honored to be selected to be part of CIP and we look forward to working with Charles River as we develop our treatments for patients that are at a high risk of death following an Acute Myocardial Infarction and other cardiac diseases where endogenous regeneration of heart muscle and reprogramming is required to restore heart function."
Bhawanjit Brar, PhD, CEO, CSO, and Founder, Jaan Biotherapeutics, Inc.
Hear from CIP/CAP Participants
- Nurturing the Next Generation of Advanced Therapy and Technology Developers
- Joining Elly’s Team to Drive Rare Disease Drug Development
- A Commitment to Incubating Promising Drug Developers
- On a Mission to Enable Advanced Therapy Technologies
- Building the Backbone: T Cell Therapies Take the Next Step to Trials
- Next-Gen Gene Therapy to Navigate Debilitating Pain Disorders
Speaking at the 2025 Cell & Gene Therapy Summit in San Francisco, CIP participant Chih-Wen Ni, Founder and CEO, NVI Therapeutics, shares his experiences:
"By joining the CIP, NVI Therapeutics aims to accelerate the development of our non-viral gene insertion platform through strategic business development support and expert mentorship. Access to Charles River's extensive network will be invaluable and collaboration with their world-class team will streamline our preclinical studies and help fast-track our path to the clinic."
Chih-Wen Ni, Ph.D., Founder and CEO, NVI Therapeutics, Inc.
Bridging Innovation and Investment
Early-stage CGT developers can raise up to $5 million per year through crowdfunding via the BioTech Funding Portal, enhancing access for Incubator and Accelerator Program participants.
Read the Story